Biotech stocks for your portfolio: Celldex Therapeutics,

New Post Public Reply Private Reply Replies (0) Message Board
fitzkarz

Biotech stocks for your portfolio: Celldex Therapeutics, Inc. (CLDX), Dynavax Technologies Corporation (DVAX)
Advertisement

Celldex Therapeutics, Inc. (CLDX) ended last trading session with a change of 0.23 percent. It trades at an average volume of 4.10M shares versus 3.8M shares recorded at the end of last trading session. The share price of $4.38 is at a distance of 47.97 percent from its 52-week low and down -85.54 percent versus its peak. The company has a market cap of $432.09M and currently has 98.65M shares outstanding. The share price is currently 21.62 percent versus its SMA20, -28.31 percent versus its SMA50, and -69.08 percent versus its SMA200. The stock has a weekly performance of 18.06 percent and is -72.07 percent year-to-date as of the recent close.

Celldex Therapeutics, Inc. (CLDX) on February 25, 2016 reported financial highlights for the fourth quarter and year ended December 31, 2015.

Cash position: Cash, cash equivalents and marketable securities as of December 31, 2015 were $289.9 million compared to $304.6 million as of September 30, 2015. The decrease was primarily driven by our fourth quarter cash used in operating activities of approximately $22.9 million, partly offset by the receipt of $9.2 million from the sale of New Jersey tax benefits. As of December 31, 2015 Celldex had 98.7 million shares outstanding.

Revenues: Total revenue was $1.8 million in the fourth quarter of 2015 and $5.5 million for the twelve months ended December 31, 2015, compared to $1.5 million and $3.6 million for the comparable periods in 2014. The increase in revenue was primarily due to our clinical trial collaboration with Bristol-Myers Squibb and our research and development agreement with Rockefeller University.

R&D Expenses: Research and development (R&D) expenses were $23.9 million in the fourth quarter of 2015 and $100.2 million for the twelve months ended December 31, 2015, compared to $27.0 million and $104.4 million for the comparable periods in 2014. R&D expenses include stock-based compensation expense of $2.0 million and $6.2 million in the three- and twelve-month periods ended December 31, 2015 compared to $1.1 million and $3.5 million for the comparable periods in 2014.

G&A Expenses: General and administrative (G&A) expenses were $11.1 million in the fourth quarter of 2015 and $33.8 million for the twelve months ended December 31, 2015, compared to $6.2 million and $20.6 million for the comparable periods in 2014. The increase in G&A expenses was primarily attributable to higher personnel-related expenses as we prepare for potential commercialization and a $6.5 million increase in RINTEGA and glembatumumab vedotin commercial planning costs in 2015 as compared to 2014. G&A expenses include stock-based compensation expense of $2.1 million and $6.6 million in the three- and twelve-month periods ended December 31, 2015 compared to $1.0 million and $3.4 million for the comparable periods in 2014.

Net loss: Net loss was $32.7 million, or ($0.33) per share, for the fourth quarter of 2015 and $127.2 million, or ($1.31) per share, for the twelve months ended December 31, 2015, compared to a net loss of $31.8 million, or ($0.36) per share, and $118.1 million, or ($1.32) per share, for the comparable periods in 2014.

Dynavax Technologies Corporation (DVAX) recently recorded 0.37 percent change and currently at $21.50 is 38.53 percent away from its 52-week low and down -33.83 percent versus its peak. It has a past 5-day performance of 16.72 percent and trades at an average volume of 1.22M shares. The stock has a 1-month performance of 26.1 percent and is -11.01 percent year-to-date as of the recent close. There were about 36.73M shares outstanding which made its market cap $789.70M. The share price is currently 20.49 percent versus its SMA20, 11.12 percent versus its SMA50, and -12.06 percent versus its SMA200.

Dynavax Technologies Corporation (DVAX) on March 30, 2016 announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for HEPLISAV-B™, the company’s vaccine candidate for immunization against hepatitis B infection in adults 18 years of age and older. The FDA has established September 15, 2016 as the Prescription Drug User Fee Act (PDUFA) action date.

The HEPLISAV-B BLA is based on positive immunogenicity results from clinical trials that have generated safety data in more than 10,000 participants. Results of these trials showed that two doses of HEPLISAV-B given one month apart provides significantly higher rates of protection with an equivalent safety profile compared to three doses of Engerix-B, a currently marketed hepatitis B vaccine that is administered over six months. In Phase 3 studies across all participants, HEPLISAV-B achieved peak seroprotection rates of 95.7 percent compared with 79.5 percent for Engerix-B. Additionally, in more than 1,100 participants with diabetes, HEPLISAV-B provided seroprotection rates of 90 percent compared to 65.1 percent for Engerix-B.

I'm in it to win it!

NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.

I was born with it, I'm truly blessed!


Alway's searching for winners'
937206596_images.jpg
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Fractional CIOs Bring Order to Growing Technology Chaos

Updated Category News Views 270

A company can outgrow its technology habits long before anyone notices the smoke. One day the owner is approving another software subscription, the office manager is chasing an internet provider, and the tech person is putting out password fires. None of that looks dramatic in isolation. Together, it is a business operating without a map. That is the useful point in the...

Continue Reading
AutoShop Answers Extends 2027 Training Into Fridays

Updated Category News Views 0

A repair bay can hum all day while the back office quietly bleeds profit. That unglamorous reality is why AutoShop Answers adding nine Friday specialty classes to its 2027 Key2Key Weekend calendar deserves a closer look. This is not a new tool chest or some vague motivational roadshow; it is an attempt to give independent shop owners an extra day to work on the pieces...

Continue Reading
UAE Ties Diplomacy, Media and AI Into a Shared Signal

Updated Category News Views 128

Influence is getting harder to measure, and easier to squander, which is why the message from Ajman deserves more than a polite nod. At the 2026 Ajman Media Forum, THE SIGNAL, Foreign Affairs Undersecretary Omar Obaid Alhesan Alshamsi made the UAE’s position plain: diplomacy and media are no longer separate lanes. Both operate on words, context, trust and the difficult...

Continue Reading
PettiChat’s Digital Pet Twin Has Real Consumer Pull

Updated Category News Views 410

A Collar Gadget Is Chasing the Empty-House Problem Leave a dog or cat alone for a few hours and plenty of owners turn into amateur detectives. Did the cat eat? Has the dog been pacing? Why was that one weird noise caught on the home camera? Seattle startup PettiChat is trying to turn that itch into a product category with PettiLive!, a screen-based version of a pet that...

Continue Reading
Global Child Tests Purpose Travel's Expanding Media Reach

Updated Category News Views 45

Celebrity travel programming usually melts into the wallpaper, but Global Child is trying to make the scenery answer for itself. Its new season of Global Child “Travel & Purpose” puts Andrea Bocelli in Tuscany, Isabela Merced in Peru and John Malkovich in Croatia, while tying each destination to a broader local-good mission. That is a more thoughtful pitch than...

Continue Reading
UAE Trust Model Faces Its Hardest Test During Crisis

Updated Category News Views 385

A country’s reputation is usually invisible right up until the machinery rattles. Then people, investors, trading partners and residents stop listening to polished slogans and start watching whether airports function, services hold up, information arrives, and business can keep moving. That was the useful core of Saeed Al Eter’s remarks at Ajman Media Forum 2026: soft...

Continue Reading
Ajman Memory Gives Heritage a Durable Digital Backbone

Updated Category News Views 303

Archives usually get applause only after somebody realizes a piece of history has vanished. Ajman is trying to skip that miserable part. During the Ajman Media Forum 2026, held November 18 and 19 at the Emirates Hospitality Centre, the emirate launched Ajman Memory, a project built to collect, document and preserve photographs, papers and video recording its development....

Continue Reading
Isar’s Nova Scotia Pad Build Gives MAXQ a Real Test

Updated Category News Views 666

Concrete work is where space ambition stops being a brochure. Isar Aerospace has taken operational responsibility for its dedicated launch infrastructure at Spaceport Nova Scotia, and construction is beginning on the Canadian launch pad it will use. For Maritime Launch Services, this is the sort of update that deserves more than the usual starry-eyed applause. A Site...

Continue Reading
EyePoint Lawsuit Puts DURAVYU Claims Under a Microscope

Updated Category News Views 0

Nothing makes biotech investors reach for the aspirin faster than a lawsuit centered on whether a drug worked as advertised. EyePoint, Inc. is facing a proposed federal securities class action alleging that the company overstated the effectiveness of DURAVYU and, by extension, its clinical, regulatory, and commercial prospects. That is a serious allegation, but it remains...

Continue Reading
DataBeyond Puts AI Sorting Before a Waste Mountain

Updated Category News Views 191

Trash is a lousy place to look for technological glamour, which is precisely why DataBeyond's COP31 appearance deserves a sober look. On November 19 in Antalya, Türkiye, the Hangzhou-based equipment provider used a China Pavilion event to lay out its case for AI, optical sensing and robots in resource recovery. That is not a magic-green headline. It is a practical...

Continue Reading

Top 5 Most Recently Viewed Articles

Understanding Investor Sentiment and Trends on SNAP Options

Updated Category News Views 251

Understanding Investor Sentiment and Trends on SNAP Options Investors are showing an intriguing trend towards Snap (NASDAQ: SNAP) as they engage in notable options trading activities, indicating a potential shift in market dynamics that shouldn't be overlooked. Our examination of public options records reveals that significant players are backing a more optimistic outlook...

Continue Reading
StarKist Partners with Kyle Busch Family for Exciting Season

Updated Category News Views 202

StarKist and the Busch Family Kick Off NASCAR 2026 As the exhilarating NASCAR season launches, StarKist Co. is excited to announce its partnership with NASCAR champion Kyle Busch, wellness advocate Samantha Busch, and young racer Brexton Busch. Building upon a successful initial year, this collaboration emphasizes the importance of healthy, ready-to-eat protein options...

Continue Reading
Teva's Upcoming Presentations at Leading Healthcare Conferences

Updated Category News Views 166

Teva's Upcoming Presentations at Major Investor Conferences In a significant announcement, Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) is set to showcase its commitment to healthcare innovation. Richard Francis, the esteemed President and CEO of Teva, will represent the company at two prestigious investor conferences this September. Morgan Stanley Global Healthcare...

Continue Reading
Earth Animal Celebrates the Holiday Season with Giving Back

Updated Category News Views 63

Earth Animal's Heartwarming Holiday Initiative This holiday season, Earth Animal has kicked off a touching initiative called "Buy Joy to Gift Joy," which aims to make a difference in the lives of shelter dogs. In collaboration with Greater Good Charities, for every Pumpkin Spice or Holiday Feast No-Hide Chew sold, the company will donate one No-Hide® Strip to a shelter...

Continue Reading
Elderly American Sentenced in Russia Amid Rising Tensions

Updated Category News Views 71

Understanding the Sentencing of Stephen Hubbard A Moscow court has sentenced Stephen Hubbard, a 72-year-old American citizen, to six years and 10 months in prison for alleged involvement in combat against Russian forces alongside a Ukrainian unit. This case marks a significant moment, as it is the first instance of an American receiving imprisonment on 'mercenary' grounds...

Continue Reading